Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Other Non-Current Liabilities (2016 - 2025)

IGC Pharma (IGC) has disclosed Other Non-Current Liabilities for 14 consecutive years, with $16000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 20.0% to $16000.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $16000.0, a 20.0% decrease, with the full-year FY2025 number at $16000.0, down 20.0% from a year prior.
  • Other Non-Current Liabilities was $16000.0 for Q1 2025 at IGC Pharma, roughly flat from $16000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $21000.0 in Q1 2023 to a low of $15000.0 in Q1 2021.
  • A 5-year average of $17058.8 and a median of $16000.0 in 2022 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: soared 31.25% in 2023, then dropped 20.0% in 2025.
  • IGC Pharma's Other Non-Current Liabilities stood at $15000.0 in 2021, then changed by 0.0% to $15000.0 in 2022, then rose by 13.33% to $17000.0 in 2023, then fell by 5.88% to $16000.0 in 2024, then changed by 0.0% to $16000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Other Non-Current Liabilities are $16000.0 (Q1 2025), $16000.0 (Q4 2024), and $20000.0 (Q3 2024).